Inozyme Pharma acquires Alexion’s ENPP1 gene deficiency program assets

Inozyme Pharma said that it has acquired Alexion Pharmaceuticals’ intellectual property and assets focused on ENPP1 gene deficiencies for an undisclosed price. The acquisition is ... Read More